The global intravenous iron drugs market is projected to grow from USD 3.84 billion in 2025 to around USD 8.19 billion by 2034, expanding at a CAGR of 8.78%. This growth is driven by the increasing prevalence of iron deficiency anemia, rising awareness among healthcare professionals, and the enhanced efficacy of intravenous formulations over oral iron supplements.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Intravenous Iron Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Intravenous Iron Drugs Market Revenue and Volume, by Product
8.1.1. Iron Sucrose
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Iron Dextran
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Ferric Carboxymaltose
8.1.3.1. Market Revenue and Volume Forecast
9.1. Intravenous Iron Drugs Market Revenue and Volume, by Application
9.1.1. Chronic Kidney Disease
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Inflammatory Bowel Disease
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Cancer
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Other Disease
9.1.4.1. Market Revenue and Volume Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Product
10.1.2. Market Revenue and Volume Forecast, by Application
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Product
10.1.3.2. Market Revenue and Volume Forecast, by Application
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Product
10.1.4.2. Market Revenue and Volume Forecast, by Application
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Product
10.2.2. Market Revenue and Volume Forecast, by Application
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Product
10.2.3.2. Market Revenue and Volume Forecast, by Application
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Product
10.2.4.2. Market Revenue and Volume Forecast, by Application
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Product
10.2.5.2. Market Revenue and Volume Forecast, by Application
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Product
10.2.6.2. Market Revenue and Volume Forecast, by Application
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Product
10.3.2. Market Revenue and Volume Forecast, by Application
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Product
10.3.3.2. Market Revenue and Volume Forecast, by Application
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Product
10.3.4.2. Market Revenue and Volume Forecast, by Application
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Product
10.3.5.2. Market Revenue and Volume Forecast, by Application
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Product
10.3.6.2. Market Revenue and Volume Forecast, by Application
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Product
10.4.2. Market Revenue and Volume Forecast, by Application
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Product
10.4.3.2. Market Revenue and Volume Forecast, by Application
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Product
10.4.4.2. Market Revenue and Volume Forecast, by Application
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Product
10.4.5.2. Market Revenue and Volume Forecast, by Application
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Product
10.4.6.2. Market Revenue and Volume Forecast, by Application
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Product
10.5.2. Market Revenue and Volume Forecast, by Application
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Product
10.5.3.2. Market Revenue and Volume Forecast, by Application
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Product
10.5.4.2. Market Revenue and Volume Forecast, by Application
11.1. Allergan Plc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. AMAG Pharmaceuticals, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Daiichi Sankyo, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Luitpold Pharmaceuticals, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. American Regent, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Pharmacosmos A/S
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Sanofi US
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Vifor Pharma Ltd.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description